IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients

[1] Hernandez N(2010)Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice Acta Gastroenterol Latinoam 40 117-121

[2] Mescia G(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet (London, England) 358 958-965

[3] Pollio C(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355

[4] Robaina G(2006)Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 1350-401

[5] Quintana L(2009)Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399-1104

[6] Bianchi C(2009)IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100-1109

[7] Manns MP(2009)Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105-801

[8] McHutchison JG(2009)Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 798-1526

[9] Gordon SC(2011)Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin Hepatology 54 1518-1345

[10] Rustgi VK(2010)Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 1338-684

[1] Hernandez N(2010)Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice Acta Gastroenterol Latinoam 40 117-121

[2] Mescia G(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet (London, England) 358 958-965

[3] Pollio C(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355

[4] Robaina G(2006)Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 1350-401

[5] Quintana L(2009)Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399-1104

[6] Bianchi C(2009)IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100-1109

[7] Manns MP(2009)Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105-801

[8] McHutchison JG(2009)Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 798-1526

[9] Gordon SC(2011)Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin Hepatology 54 1518-1345

[10] Rustgi VK(2010)Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 1338-684